[Edaily Reporter KIM SUNG-JIN ] On the 19th, stock prices in the domestic pharmaceutical and biotech market showed mixed results, driven by new drug development achievements and expectations regarding inclusion in major indices. PenetriumBio’s stock price surged on news that a positive therapeutic response was confirmed in early-stage clinical trials of a prostate cancer treatment candidate, while AprilBio Co.,Ltd. also posted strong gains following news of its inclusion in the KOSDAQ 150 Index.
In contrast, stock performance varied among AriBio-related stocks. ARIBIOLAB, which had hit the daily price limit the previous day, continued its upward trend, but its holding company, AriBio Holdings, could not avoid a decline in its stock price. Although both companies are related to AriBio’s Alzheimer’s disease treatment “AR1001,” analysts attribute the difference in performance to their distinct corporate structures and financial situations.
PenetriumBio Soars 17%… Attention on Prostate Cancer Clinical Results
According to KG Zeroin MP Doctor, PenetriumBio closed at 6,750 won on the day, up 17.19% from the previous trading day. This is interpreted as a positive impact on investor sentiment following news that a therapeutic response was confirmed in patients receiving the prostate cancer drug candidate “Penetrium (CP-PCA07)” in combination with existing anticancer drugs during an early-stage clinical trial. PenetriumBio stock price trend. (Source: KG Zeroin.) HYUNDAI BIOSCIENCE CO., LTD., the parent company of PenetriumBio, announced today that in a Phase 1 clinical trial for metastatic castration-resistant prostate cancer currently underway at Seoul National University Hospital, Penetrium was administered in combination with existing anticancer drugs to two patients who had developed resistance to those drugs, resulting in a decrease in prostate-specific antigen (PSA) levels in both patients. This information was disclosed to shareholders via a public notice the previous day (the 18th).
Penitrium is a drug candidate currently in development aimed at restoring treatment response in patients who have developed resistance to existing anticancer drugs. HYUNDAI BIOSCIENCE CO., LTD. is focusing specifically on the phenomenon of “pseudo-resistance.” This refers to the tumor microenvironment surrounding cancer cells interfering with the action of anticancer drugs. The hypothesis is that even if existing anticancer drugs retain their ability to attack cancer cells, they may not be able to act effectively due to structural barriers around the tumor.
According to HYUNDAI BIOSCIENCE CO., LTD., this pseudo-resistance occurs with repeated administration of anticancer drugs; specifically, before genetic mutations occur, the tissue surrounding the cancer cells hardens, creating a physical barrier that blocks drug penetration.
Penitrium is being developed as a strategy to improve this environment and enhance the efficacy of existing anticancer drugs. According to HYUNDAI BIOSCIENCE CO., LTD., patients in this clinical trial who received the combination of enzalutamide and Penitrium had shown a diminished response to prior treatment but exhibited a continuous decline in PSA levels following Penitrium administration. PSA is a blood test marker used to evaluate the course of prostate cancer treatment. However, given that these are preliminary results observed in only two patients, caution is warranted in interpreting the data.
Penitrium is also currently undergoing clinical trials overseas. Last September, Penitrium received approval from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2a clinical trial targeting patients with recurrent and refractory advanced solid tumors.
AprilBio Co.,Ltd. Rises on Inclusion in KOSDAQ 150 Index
AprilBio Co.,Ltd. also posted gains on the day. The stock closed at 13,130 won, up 14.67% from the previous trading day.
The news of its inclusion in the KOSDAQ 150 index is cited as the main reason for the stock’s rise. On the 18th, the Korea Exchange announced the results of its regular review of major representative indices, including the KOSPI 200, KOSDAQ 150, and KRX 300, and AprilBio Co.,Ltd. was newly added to the KOSDAQ 150 index as part of this review. Other pharmaceutical, biotech, and healthcare companies included in the revisions were Rznomics Inc., LivsMed Inc., Qurient Co., Ltd., DongKook Pharmaceutical Co.,Ltd., and SEERS. AprilBio Co.,Ltd. stock price trend. (Source: KG Zeroin.) The revised index composition will take effect on December 11. Exchange-traded funds (ETFs) and index funds that track the KOSDAQ 150 Index must adjust their holdings in line with the changes to the index constituents. As a result, newly included stocks tend to see heightened expectations for future inflows of passive investment funds.
However, inclusion in the index does not guarantee long-term stock price appreciation. This is because the actual amount of capital inflows may vary depending on the stock’s weighting within the index and the asset size of the index-tracking funds. Furthermore, it is important to bear in mind the possibility that expectations of index inclusion may already be factored into the stock price in advance.
AprilBio Co.,Ltd. has also recently faced uncertainties in its new drug development process. In 2021, AprilBio Co.,Ltd. licensed its autoimmune disease treatment candidate “APB-A1” to the Danish pharmaceutical company Lundbeck for a total of $448 million; however, Lundbeck announced last August that it was halting development of “APB-A1” for the indication of thyroid-associated ophthalmopathy. This decision followed the failure to confirm the level of therapeutic efficacy expected in clinical trials.
However, since Lundbeck has not halted development of the candidate compound itself, observers note that the company has avoided the worst-case scenario. In its third-quarter earnings report released on the 11th, Lundbeck stated that it is maintaining “APB-A1” in its Phase 1 clinical pipeline and is reviewing the possibility of further development for other indications in the field of neurological disorders.
On the 9th, AprilBio Co.,Ltd. held a research and development (R&D) event and announced plans to pursue technology licensing for three new pipeline candidates. “APB-I-005,” a treatment for autoimmune diseases, is a dual-target therapy that simultaneously inhibits TL1A and IL-23p19, both associated with inflammatory bowel disease; the company plans to conduct preclinical toxicity tests next year. For the metabolic disease siRNA therapy “APB-O-001,” the company is currently conducting validation tests to independently replicate the efficacy of the licensed technology. In the oncology field, the company is embarking on the development of the ADC therapy “APB-A-001,” which simultaneously targets c-Met and VEGF.
An AprilBio Co.,Ltd. official stated, “Today’s rise in the stock price appears to have been influenced by the company’s inclusion in the KOSDAQ 150 Index.”
ARIBIOLAB Rises, Holdings Falls… Mixed Investor Sentiment Toward the Same New Drug
It was notable that ARIBIOLAB-related stocks showed divergent price trends following the announcement of global Phase 3 clinical trial data for an oral Alzheimer’s disease treatment. Since announcing the top-line results of the global Phase 3 clinical trial on the 17th, ARIBIOLAB and AriBio Holdings have experienced a roller-coaster ride, falling to the daily price limit one day and hitting the daily price ceiling the next. However, on this day, while ARIBIOLAB’s stock price continued its upward trend, AriBio Holdings’ stock price actually fell, revealing a divergence in their performance. ARIBIOLAB stock price trend. (Source: KG Zeroin.) ARIBIOLAB closed at 5,820 won this afternoon, up 10% from the previous trading day. In contrast, AriBio Holdings closed at 2,980 won, down 4.33% from the previous day’s closing price. Analysts attribute this divergence in stock performance to the group’s corporate governance structure.
AriBio Holdings, formerly listed under the name Solux Co., Ltd., had been pursuing a merger with AriBio, an unlisted new drug developer, but withdrew that plan last September. With the merger—which had initially been viewed as AriBio’s pathway to the KOSDAQ market—now off the table, attention is focusing on the group’s future corporate governance and listing strategy.
Meanwhile, ARIBIOLAB has recently seen an expansion in direct equity investments and business ties with AriBio. In September, AriBio and AriBio Holdings decided to invest a total of 18 billion won in ARIBIOLAB, with AriBio contributing 15 billion won and AriBio Holdings contributing 3 billion won.
Once the payment for the rights offering scheduled for the 30th is completed, AriBio will secure a 15.9% stake in ARIBIOLAB and become the largest shareholder, while AriBio Holdings is expected to become the second-largest shareholder with a 14.1% stake. The corporate governance structure will shift from the existing model centered on AriBio Holdings to one in which the unlisted AriBio directly controls the listed company ARIBIOLAB. AriBio Holdings stock price trend. (Source: KG Zeroin.)
Just before Anthropic, the U.S. artificial intelligence (AI) developer behind “Clod,” went public on the Nasdaq, the iShares Bitcoin Trust (IBIT)—BlackRock’s iShares Bitcoin Trust, the largest Bitcoin…
Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…